Published in J Clin Psychopharmacol on February 01, 1994
Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet (2000) 3.05
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl (1990) 1.05
Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry (1999) 1.03
Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiatry Neurosci (1995) 0.97
Gender differences in association between serotonin transporter gene polymorphism and personality traits. Psychiatr Genet (2000) 0.95
Low temperature sustains inhibition of angiotensin-converting-enzyme activity in serum from patients taking captopril. N Engl J Med (1981) 0.93
An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci (2000) 0.92
Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Psychiatry Res (1997) 0.87
Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res (1999) 0.86
A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci (1995) 0.86
Serotonergic genes and suicidality. Crisis (2001) 0.83
A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. J Clin Psychopharmacol (1998) 0.83
Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics (1995) 0.83
Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med (2008) 0.82
Tryptophan hydroxylase gene 218A/C polymorphism is associated with somatic anxiety in major depressive disorder. J Affect Disord (2001) 0.82
Reduction in suicidal ideation with SSRIs: a review of 459 depressed patients. J Psychiatry Neurosci (1993) 0.82
Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol (1999) 0.81
Preparatory brain potentials in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.81
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord (1999) 0.81
Event-related potentials and selective attention in major depressive illness. J Affect Disord (1991) 0.79
SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int Clin Psychopharmacol (1995) 0.78
Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry (1994) 0.78
Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther Drug Monit (1990) 0.78
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord (1994) 0.77
Synthesis and characterization of an aryl-azidoparoxetine. A novel photo-affinity probe for serotonin-transporter. Biochem Pharmacol (1995) 0.77
Brainstem evoked potentials in panic disorder. J Psychiatry Neurosci (1994) 0.77
Platelet 3H imipramine binding: a possible predictor of response to antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.76
Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety (1996) 0.76
Quantitative EEG correlates of panic disorder. Psychiatry Res (1996) 0.76
Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies. Clin Neuropharmacol (1992) 0.75
A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci (1992) 0.75
Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol (1993) 0.75
Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients. J Psychiatry Neurosci (1991) 0.75
A comparison of patients with major depressive disorder recruited through newspaper advertising versus consultation referrals for clinical drug trials. Psychopharmacol Bull (1997) 0.75
A comparison of placebo response with major depressive disorder in patients recruited through newspaper advertising versus consultation referrals. Psychopharmacol Bull (1997) 0.75
ECNP position paper on social phobia proceedings from an ECNP workshop in Jerusalem, October 1994. Eur Neuropsychopharmacol (1996) 0.75
Antidepressant plasma levels and clinical response in depressed patients treated with oxaprotiline and doxepin. Int Clin Psychopharmacol (1988) 0.75
Disulfiram and bipolar affective disorder: a case report. J Clin Psychopharmacol (1986) 0.75
Myalgia with the new generation antidepressants. J Clin Psychopharmacol (1986) 0.75
Dysthymia and serotonin. Int Clin Psychopharmacol (1993) 0.75
Relaxation-induced EEG alterations in panic disorder patients. J Anxiety Disord (1997) 0.75